Presentations

Upcoming Presentations

There are no upcoming presentations at this time.

Past Presentations

August 12, 2015
Anti PD-1 Targeted Therapy and Predictive Biomarkers in Melanoma
Shahla Riazi, MD, PhD
2015 Master of Science in Clinical and Translational Medicine (MS-CTR) Capstone Presentations
Georgetown University
Washington, DC

April 27, 2015
FDA 2015 ORSI Science Symosium 
Silver Spring, MD

Targeting Triple Negative Breast Cancer in African-American Women
Luciane Cavalli, PhD

Knowledge Regarding Antidepressant Medication among Depressed Latino Patients in Primary Care
Bonnie L. Green, PhD

Literature mining, curation and standardization to develop evidence for biomarkers that predict response to cancer therapy
Shruti Rao, MS

Health Literacy and Information Regarding Medical Products Supporting Aging in Place
Pamela A. Saunders, PhD

April 22, 2015
Array-CGH and miRNA expression profiling of triple negative breast cancer in African-American women
Luciane R. Cavalli, PhD
American Association for Cancer Research – Annual Meeting 
Philadelphia, PA

March 26, 2015
Identification of miRNA targets in triple negative breast cancer from Latinas
Luciane R. Cavalli, PhD
Symposium on Global Cancer Research 
Boston, MA               
Abstract: Triple negative breast cancer (TNBC) account for 10-17% of all breast cancers and are defined by the low or lack of expression of ER, PR and HER2 receptors. These tumors are more commonly seen in younger women of African and Latinas/Hispanic descents, usually diagnosed at more advanced stages, with non-localized disease. Molecular studies have shown differences in the biology of these tumors in Latinas as key contributors for high mortality. Aims: The main goal of our study was to investigate the biological factors that may be associated with poor prognosis in a group of Latina patients with TNBC.

December 4, 2014
Considerations for Sharing Clinical Trial Data
Erin Wilhelm, MPH
Association of Academic Health Centers (AAHC) Annual Research Meeting
Washington, DC
Abstract: The generation, dissemination, and sharing of research data are key ingredients in contributing to scientific progress and the public good. Data sharing has been encouraged to facilitate open, team-based science within the clinical research enterprise, across traditional boundaries, and ultimately improve the development of medical products and benefit public health. But sharing data is complex. This presentation identifies and examines approaches and cost considerations involved in sharing participant-level clinical research data.

April 9, 2014
An integrated framework for the pharmacogenomic characterization of oncological drug response to enable precision medicine
Krithika Bhuvaneshwar MS, Michael Harris MA, Thanemozhi Natarajan PhD, Laura Sheahan PhD, John Deeken MD, Subha Madhavan, PhD, MS
American Medical Informatics Association (AMIA) Joint Summits on Translational Science 
San Francisco, CA
Abstract: Response to the oncology drug gemcitabine may be variable in part due to genetic differences in the enzymes and transporters responsible for its metabolism and disposition. The aim of our in-silico study was to identify gene variants significantly associated with gemcitabine response that may help to personalize treatment in the clinic.

October 2, 2014
GVISR: Georgetown Vaccine Information Safety Resource
Peter B. McGarvey PhD, Baris E. Suzek PhD, James N. Baraniuk MD, Shruti Rao MS, Brian Conkright MS, Samir Lababidi PhD, Andrea Sutherland MD MPH MSc, Richard Forshee PhD, Subha Madhavan PhD MS
Georgetown University Innovation Center for Biomedical Informatics
Annual Bioinformatics Symposium 2014 
Washington, DC           
Abstract: Near universal administration of vaccines mandates intense pharmacovigilance for vaccine safety and a stringently low tolerance for adverse events. Reports of autoimmune diseases (AID) following vaccination have been challenging to evaluate given the high rates of vaccination, background incidence of autoimmunity, and low incidence and variable times for onset of AID after vaccinations. In order to identify biologically plausible pathways to adverse autoimmune events of vaccine-related AID, we used a systems biology approach to create a matrix of innate and adaptive immune mechanisms active in specific diseases, responses to vaccine antigens, adjuvants, preservatives and stabilizers, for the most common vaccine-associated AID found in the Vaccine Adverse Event Reporting System

October 2, 2014
Targeting Triple Negative Breast Cancer in African American Women
Subha Madhavan PhD MS, Luciane R. Cavalli PhD
Georgetown University Innovation Center for Biomedical Informatics
Annual Bioinformatics Symposium 2014 
Washington, DC                                                                      
Abstract: The objective of this study is to identify molecular markers in TNBC patients for drug discovery research and personalized medicine. This research will provide the infrastructure, data, and tools to analyze multi-omics data from TNBC samples to help reviewers at the FDA use this framework for new, targeted therapies in breast cancer.

September 22, 2013
In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseases
Peter B. McGarvey PhD, Baris E. Suzek PhD, James N. Baraniuk MD, Shruti Rao MS, Brian Conkright MS, Samir Lababidi PhD, Andrea Sutherland MD MPH MSc, Richard Forshee PhD, Subha Madhavan PhD MS
Association for Computing Machinery (ACM) Bioinformatics Computational Biology, and Biomedical Informatics (BCB) 2013 Conference  
Washington, DC                
Abstract: Near universal administration of vaccines mandates intense pharmacovigilance for vaccine safety and a stringently low tolerance for adverse events. Reports of autoimmune diseases (AID) following vaccination have been challenging to evaluate given the high rates of vaccination, background incidence of autoimmunity, and low incidence and variable times for onset of AID after vaccinations. In order to identify biologically plausible pathways to adverse autoimmune events of vaccine-related AID, we used a systems biology approach to create a matrix of innate and adaptive immune mechanisms active in specific diseases, responses to vaccine antigens, adjuvants, preservatives and stabilizers, for the most common vaccine-associated AID found in the Vaccine Adverse Event Reporting System.